CF Industries Holdings, Inc. vs TransMedics Group Inc — how do they compare? CF Industries Holdings, Inc. trades at $115.13 (market cap $18.31B), while TransMedics Group Inc trades at $76.2 (market cap $2.58B). The key difference: CF Industries Holdings, Inc. is far larger — about 7.1× TransMedics Group Inc's market cap, and CF Industries Holdings, Inc. pays a 2.01% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| CF | TMDX | |
|---|---|---|
Market Cap | $18.31B | $2.58B |
Sector | Basic Materials | Technology |
52-Week High | $137.55 | $150.42 |
52-Week Low | $76.08 | $61.99 |
Enterprise Value | $19.89B | $2.98B |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
CF Industries stock trades at $120.92, up 3.42% today, with a bullish technical outlook and strong fundamentals. Recent earnings beats, a 20% dividend hike announced July 8, 2026, and robust profitability metrics like a 23.73% net margin support investor confidence. The stock is near consensus price targets, with moving averages signaling upward momentum.
The outlook is positive, driven by firm nitrogen demand and shareholder returns, but risks include input cost pressures and cyclical industry headwinds. Upside potential exists if earnings continue to exceed expectations, though overbought RSI levels suggest near-term consolidation may occur.
TransMedics (TMDX) trades at $75.74, up 6.33% today, showing strong momentum despite a recent earnings miss. The stock maintains bullish technical signals with support at $75 and resistance at $77. Recent strategic investments in European organ logistics through PAD Aviation position the company for international expansion, though margin pressure from these investments remains a concern. Analyst consensus remains strongly positive with a $108.71 price target.
The outlook remains favorable with 75% analyst buy ratings and significant upside potential from current levels. Key risks include execution challenges in European expansion, ongoing margin pressure from NOP investments, and competitive threats in the transplant logistics space. Revenue growth continues at 21% year-over-year, but investors should monitor margin trends and European rollout execution closely.
Trailing returns across standard periods
Latest headlines on both assets
CF Industries is a leading producer and distributor of nitrogen fertilizers. The company operates seven nitrogen facilities in North America and holds joint venture interests in further production capacity in the United Kingdom and Trinidad and Tobago. CF makes nitrogen primarily using low-cost U.S. natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally.
Read more on CF →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →